JP Morgan Chase’s Xenon Pharmaceuticals XENE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$1.63M Buy
+29,400
New +$1.35M ﹤0.01% 4264
2024
Q1
Sell
-30,000
Closed -$1.38M 7943
2023
Q4
$1.38M Buy
+30,000
New +$1.06M ﹤0.01% 4113
2021
Q4
Sell
-118,200
Closed -$1.81M 7005
2021
Q3
$1.81M Buy
+118,200
New +$2.05M ﹤0.01% 3867

Other funds holding XENE

JP Morgan Chase's XENE Position: Q1 2026 in Review

JP Morgan Chase increased its Xenon Pharmaceuticals (XENE) stake by 29% in Q1 2026, buying an estimated $19.8M and bringing the position to 1,923,610 shares worth $107M. The position accounts for 0.01% of the portfolio, ranked #948.

JP Morgan Chase first reported a position in XENE in Q2 2016 and has held it in 35 quarters since. 290 funds tracked by Wall St. Rank hold XENE as of Q1 2026.

  • JP Morgan Chase held 1,923,610 shares of Xenon Pharmaceuticals worth $107M as of Q1 2026.
  • JP Morgan Chase bought 429,578 Xenon Pharmaceuticals shares in Q1 2026, an estimated $19.8M.
  • Xenon Pharmaceuticals made up 0.01% of JP Morgan Chase's portfolio in Q1 2026, its #948 holding.
  • JP Morgan Chase first reported a position in Xenon Pharmaceuticals in Q2 2016 and has held it in 35 quarters since.
  • 290 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.